- Peer-reviewed publication highlights 22 new oncogenic HER2 driver mutations identified and experimentally validated with MAP discovery engine -
CAMBRIDGE, Mass. and NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced the publication of data identifying new oncogenic HER2 allosteric mutations that support the Mutation-Allostery-Pharmacology (MAP) discovery engine’s capabilities and further suggest the need for novel inhibitors to treat HER2-mutant cancers. The paper, titled “Computational and Functional Analyses of HER2 Mutations Revealing Allosteric Activation Mechanisms and Altered Pharmacologic Effects” by Ishiyama et al. was published online by the American Association for Cancer Research (AACR)’s Cancer Research Journal on May 3, 2022.
Read more at globenewswire.com